Millennium Management LLC acquired a new stake in shares of Autolus Therapeutics Ltd – (NASDAQ:AUTL) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 145,945 shares of the company’s stock, valued at approximately $3,910,000. Millennium Management LLC owned approximately 0.38% of Autolus Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Autolus Therapeutics during the second quarter valued at approximately $132,000. TD Asset Management Inc. acquired a new stake in Autolus Therapeutics in the second quarter valued at approximately $258,000. ING Groep NV acquired a new stake in Autolus Therapeutics in the second quarter valued at approximately $402,000. Bank of Montreal Can acquired a new stake in Autolus Therapeutics in the second quarter valued at approximately $429,000. Finally, Janus Henderson Group PLC acquired a new stake in Autolus Therapeutics in the second quarter valued at approximately $498,000. Hedge funds and other institutional investors own 21.06% of the company’s stock.

Several equities research analysts have weighed in on AUTL shares. Jefferies Financial Group started coverage on shares of Autolus Therapeutics in a research note on Tuesday, July 17th. They issued a “buy” rating and a $37.00 target price for the company. William Blair started coverage on shares of Autolus Therapeutics in a research note on Tuesday, July 17th. They issued an “outperform” rating for the company. Wells Fargo & Co started coverage on shares of Autolus Therapeutics in a research note on Tuesday, July 17th. They issued an “outperform” rating and a $38.00 target price for the company. Finally, Goldman Sachs Group started coverage on shares of Autolus Therapeutics in a research note on Thursday, July 26th. They issued a “neutral” rating for the company.

Shares of AUTL opened at $31.00 on Friday. Autolus Therapeutics Ltd – has a twelve month low of $19.17 and a twelve month high of $33.50.

About Autolus Therapeutics

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Recommended Story: What is the NASDAQ Stock Market?

Institutional Ownership by Quarter for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.